Takeda Pharmaceutical (NYSE:TAK) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Saturday, December 21st, ValuEngine reports.
Several other research analysts also recently weighed in on the company. Cowen started coverage on Takeda Pharmaceutical in a research note on Friday, November 1st. They set a “market perform” rating and a $19.50 target price for the company. Jefferies Financial Group began coverage on shares of Takeda Pharmaceutical in a report on Tuesday, September 24th. They issued a “buy” rating for the company. Finally, Zacks Investment Research raised shares of Takeda Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Takeda Pharmaceutical has a consensus rating of “Hold” and an average target price of $19.25.
Shares of Takeda Pharmaceutical stock opened at $19.84 on Friday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.94 and a current ratio of 1.45. Takeda Pharmaceutical has a fifty-two week low of $16.10 and a fifty-two week high of $21.61. The firm has a 50-day simple moving average of $20.24 and a two-hundred day simple moving average of $18.12. The company has a market cap of $61.84 billion, a P/E ratio of 38.90 and a beta of 0.76.
Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.59 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 12.52% and a net margin of 3.66%. The company had revenue of $7.56 billion during the quarter. Equities research analysts forecast that Takeda Pharmaceutical will post 1.92 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Adelphi Capital LLP increased its position in shares of Takeda Pharmaceutical by 13.4% during the third quarter. Adelphi Capital LLP now owns 8,991,290 shares of the company’s stock worth $154,650,000 after purchasing an additional 1,060,174 shares in the last quarter. Macquarie Group Ltd. grew its stake in Takeda Pharmaceutical by 15.2% during the 2nd quarter. Macquarie Group Ltd. now owns 5,506,103 shares of the company’s stock valued at $97,458,000 after acquiring an additional 724,835 shares in the last quarter. Bank of America Corp DE grew its stake in Takeda Pharmaceutical by 55.8% during the 2nd quarter. Bank of America Corp DE now owns 3,742,366 shares of the company’s stock valued at $66,240,000 after acquiring an additional 1,340,772 shares in the last quarter. Mondrian Investment Partners LTD raised its holdings in Takeda Pharmaceutical by 6.7% in the 3rd quarter. Mondrian Investment Partners LTD now owns 3,639,170 shares of the company’s stock valued at $61,866,000 after acquiring an additional 229,000 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its holdings in Takeda Pharmaceutical by 15.0% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 3,158,924 shares of the company’s stock valued at $54,333,000 after acquiring an additional 411,338 shares during the last quarter. Institutional investors and hedge funds own 4.57% of the company’s stock.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Recommended Story: What is meant by a buy rating?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Takeda Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Takeda Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.
